TY - JOUR
T1 - Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
AU - Puranik, Arjun
AU - Lenehan, Patrick J.
AU - Silvert, Eli
AU - Niesen, Michiel J.M.
AU - Corchado-Garcia, Juan
AU - O'Horo, John C.
AU - Virk, Abinash
AU - Swift, Melanie D.
AU - Gordon, Joel E.
AU - Speicher, Leigh Lewis
AU - Geyer, Holly L.
AU - Kremers, Walter
AU - Halamka, John
AU - Badley, Andrew D.
AU - Venkatakrishnan, A. J.
AU - Soundararajan, Venky
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2022/1/14
Y1 - 2022/1/14
N2 - Background: mRNA coronavirus disease 2019 (COVID-19) vaccines are safe and effective, but increasing reports of breakthrough infections highlight the need to vigilantly monitor and compare the effectiveness of these vaccines. Methods: We retrospectively compared protection against symptomatic infection conferred by mRNA-1273 and BNT162b2 at Mayo Clinic sites from December 2020 to September 2021. We used a test-negative case-control design to estimate vaccine effectiveness (VE) and to compare the odds of symptomatic infection after full vaccination with mRNA-1273 versus BNT162b2, while adjusting for age, sex, race, ethnicity, geography, comorbidities, and calendar time of vaccination and testing. Findings: Both vaccines were highly effective over the study duration (VEmRNA-1273: 84.1%, 95% confidence interval [CI]: 81.6%–86.2%; VEBNT162b2: 75.6%, 95% CI: 72.2%–78.7%), but their effectiveness was reduced during July–September (VEmRNA-1273: 75.6%, 95% CI: 70.1%–80%; VEBNT162b2: 63.5%, 95% CI: 55.8%–69.9%) as compared to December–May (VEmRNA-1273: 93.7%, 95% CI: 90.4%–95.9%; VEBNT162b2: 85.7%, 95% CI: 81.4%–88.9%). Adjusted for demographic characteristics, clinical comorbidities, time of vaccination, and time of testing, the odds of experiencing a symptomatic breakthrough infection were lower after full vaccination with mRNA-1273 than with BNT162b2 (odds ratio: 0.60; 95% CI: 0.55–0.67). Conclusions: Both mRNA-1273 and BNT162b2 strongly protect against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It is imperative to continue monitoring and comparing available vaccines over time and with respect to emerging variants to inform public and global health decisions. Funding: This study was funded by nference.
AB - Background: mRNA coronavirus disease 2019 (COVID-19) vaccines are safe and effective, but increasing reports of breakthrough infections highlight the need to vigilantly monitor and compare the effectiveness of these vaccines. Methods: We retrospectively compared protection against symptomatic infection conferred by mRNA-1273 and BNT162b2 at Mayo Clinic sites from December 2020 to September 2021. We used a test-negative case-control design to estimate vaccine effectiveness (VE) and to compare the odds of symptomatic infection after full vaccination with mRNA-1273 versus BNT162b2, while adjusting for age, sex, race, ethnicity, geography, comorbidities, and calendar time of vaccination and testing. Findings: Both vaccines were highly effective over the study duration (VEmRNA-1273: 84.1%, 95% confidence interval [CI]: 81.6%–86.2%; VEBNT162b2: 75.6%, 95% CI: 72.2%–78.7%), but their effectiveness was reduced during July–September (VEmRNA-1273: 75.6%, 95% CI: 70.1%–80%; VEBNT162b2: 63.5%, 95% CI: 55.8%–69.9%) as compared to December–May (VEmRNA-1273: 93.7%, 95% CI: 90.4%–95.9%; VEBNT162b2: 85.7%, 95% CI: 81.4%–88.9%). Adjusted for demographic characteristics, clinical comorbidities, time of vaccination, and time of testing, the odds of experiencing a symptomatic breakthrough infection were lower after full vaccination with mRNA-1273 than with BNT162b2 (odds ratio: 0.60; 95% CI: 0.55–0.67). Conclusions: Both mRNA-1273 and BNT162b2 strongly protect against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It is imperative to continue monitoring and comparing available vaccines over time and with respect to emerging variants to inform public and global health decisions. Funding: This study was funded by nference.
KW - BNT162b2
KW - COVID-19
KW - SARS-CoV-2
KW - Translation to population health
KW - comparative effectiveness
KW - mRNA vaccines
KW - mRNA-1273
UR - http://www.scopus.com/inward/record.url?scp=85122280846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122280846&partnerID=8YFLogxK
U2 - 10.1016/j.medj.2021.12.002
DO - 10.1016/j.medj.2021.12.002
M3 - Article
C2 - 34927113
AN - SCOPUS:85122280846
SN - 2666-6359
VL - 3
SP - 28-41.e8
JO - Med
JF - Med
IS - 1
ER -